REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/13/2026
Back to search
Official data from USPTO
PAIGE.AI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
PAIGE.AI
ST13
US500000087843838Class
42, 44
Filing
87843838
Registration
6420234
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
58
Latest update
07/13/2026
Classification
Registered
Trademark type
Word
Nice classes
42, 44
Filing date
03/21/2018
Registration date
07/13/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/13/2021
Last transaction
07/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/20/2019
First use in commerce
02/20/2019
Drawing code
4
Owner type
03
Owner location
New York, NY, US
Examiner
CLARKE, NANCY
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
PAIGE.AI, Inc.
Representatives
Mark Leonardo NUTTER, MCCLENNEN & FISH, LLP
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Software as a service (SaaS) services featuring software for artificial intelligencemachine learningdeep learningstatistical learningdata miningcontextual prediction; software as a service (SaaS) services featuring software for use in disease pathologysoftware that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseasesstatesconditions; software as a service (SaaS) services featuring software for use in monitoring of diseasesstatesconditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseasesstatesconditions; software as a service (SaaS) services featuring software to detect the recurrence of diseasesstatesconditions; software as a service (SaaS) services featuring software to detectmonitorevaluate patients' responses to treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in clinical management of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in prevention of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes
Class 44
Medical services; cancer therapy services; medical testingthe review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseasesstatesconditions; medical testing for evaluation of prognosis relating to diseasesstatesconditions; medical testing for the monitoring of diseasesstatesconditions; medical testing to detect or identify predispositions to diseasesstatesconditions; medical testing to detect or determine the recurrence of diseasesstatesconditions; medical testing to detectmonitorevaluate responses to treatment of diseasesstatesconditions; medical testing to evaluate clinical management of diseasesstatesconditions; medical testing for selection of treatment for diseasesstatesconditions; medical testing to evaluate or facilitate prevention of diseasesstatesconditions; medical testing to selectfacilitatemonitorevaluate palliation or treatment of diseasesstates or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testingmonitoringreporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseasesstatesconditions; medical analysis or advisory services for the evaluation of prognosis relating to diseasesstatesconditions; medical analysis or advisory services relating to monitoring diseasesstatesconditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseasesstatesconditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseasesstatesconditions; medical analysis or advisory services relating to the detectionmonitoringevaluation of responses to treatment of diseasesstatesconditions; medical analysis or advisory services relating to the clinical management of diseasesstatesconditions; medical analysis or advisory services relating to the selection of treatment for diseasesstatesconditions; medical analysis or advisory services relating to the prevention of diseasesstatesconditions; medical analysis or advisory services relating to the palliation or treatment of diseasesstates or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides
Publications
History of USPTO decisions and trademark events.
58 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/17/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/17/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/17/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
07/13/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/08/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/07/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/21/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/21/2021
IUAF
USE AMENDMENT FILED
05/12/2021
EISU
TEAS STATEMENT OF USE RECEIVED
05/12/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/01/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/01/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/01/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/01/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/15/2020
EX4G
SOU EXTENSION 4 GRANTED
12/11/2020
EXT4
SOU EXTENSION 4 FILED
12/11/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/11/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/12/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/12/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/12/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/08/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/08/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/08/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/08/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/20/2020
EX3G
SOU EXTENSION 3 GRANTED
06/18/2020
EXT3
SOU EXTENSION 3 FILED
06/18/2020
EEXT
SOU TEAS EXTENSION RECEIVED
06/18/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/20/2019
EX2G
SOU EXTENSION 2 GRANTED
12/18/2019
EXT2
SOU EXTENSION 2 FILED
12/18/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/18/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/14/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/14/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/18/2019
EX1G
SOU EXTENSION 1 GRANTED
06/14/2019
EXT1
SOU EXTENSION 1 FILED
06/14/2019
EEXT
SOU TEAS EXTENSION RECEIVED
06/14/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/18/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/23/2018
PUBO
PUBLISHED FOR OPPOSITION
10/23/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/03/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/20/2018
ALIE
ASSIGNED TO LIE
09/17/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/05/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/11/2018
GNRT
NON-FINAL ACTION E-MAILED
07/11/2018
CNRT
NON-FINAL ACTION WRITTEN
07/11/2018
DOCK
ASSIGNED TO EXAMINER
07/02/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/28/2018
NWAP
NEW APPLICATION ENTERED
03/24/2018
Continuous trademark protection
Get notified about every new filing that threatens PAIGE.AI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.